The impact of the implantable cardioverter defibrillator on quality-of-life

The implantable cardioverter defibrillator (ICD) is an established treatment for patients with life-threatening ventricular arrhythmias. While it clearly reduces the incidence of death from recurrent arrhythmia, little is known about the impact on patients' quality-of-life. In this prospective study, quality-of-life was assessed by questionnaire before and after ICD implantation. The "Sickness Impact Profile" (SIP), which evaluates physical, psychosocial, and other activities, as well as functions of daily life, was used. Employment and rehospitalization rates were also examined. Twenty-one of 23 consecutive patients, aged 58 +/- 11 years, undergoing ICD implantation at Royal Perth Hospital were studied. During the 14 +/- 8 month follow-up, 4 patients died. Functional capacity was unchanged in all but one of the survivors in whom it improved from New York Heart Association Class III to II. Four of 8 survivors employed before implant have since retired. Six patients required rehospitalization on 13 occasions, problems related to arrhythmias or the ICD. Overall SIP scores preimplant (11.2 +/- 9.3; P < 0.05) were significantly worse at 6-month follow-up (21.7 +/- 18.2), but returned to preimplant levels by 12-month follow-up (8.8 +/- 10.8; NS). This was primarily due to transient problems in the areas of emotional behavior, alertness, and social interaction. SIP psychosocial dimension scores: preimplant: 7.2 +/- 9.0; 6-month: 17.8 +/- 18.1 (P < 0.05); and 12-month: 8.6 +/- 10.3 (NS). Early retirement and hospitalizations due to arrhythmias may still be expected even after implantation of an ICD; however, quality-of-life appears only to temporarily decline.

The cost-effectiveness of treatment of supraventricular arrhythmias related to an accessory atrioventricular pathway: comparison of catheter ablation, surgical division and medical treatment

BACKGROUND

Treatment alternatives for patients with incapacitating supraventricular arrhythmias related to an accessory atrioventricular pathway include transcatheter radiofrequency (RF) ablation, surgical division and long-term antiarrhythmic therapy (medical).

AIM

The aim of this study was to compare in terms of cost and efficacy, transcatheter, surgical and medical treatment of patients with incapacitating supraventricular arrhythmias resulting from an accessory pathway.

METHODS

The study population consisted of 52 patients who underwent transcatheter RF ablation (20 consecutive patients), surgical treatment (20) and medical treatment (12). Two types of economic analysis were used. In all groups, a resource based costing method was used and in the medical and surgical treatment groups, a diagnostic related group (DRG) based costing method was used.

RESULTS

Eighteen out of 20 (90%) patients who underwent catheter ablation remained asymptomatic during 8.4 +/- 1.6 months of follow-up. All surgically treated patients remained asymptomatic during 54 +/- 15 months of follow-up. Only one of the 12 patients in the medical treatment group remained completely free of symptoms during the mean 58 +/- 23 month follow-up period. The mean cost (1992 Australian dollars) per patient, calculated on the basis of actual resources used (with a DRG based costing given in brackets), was $2746 +/- $800 for catheter ablation, $12141 +/- $4465 ($12880 +/- $3998) for surgical treatment and $1713 +/- $748 ($1967 +/- $33) for medical treatment. The total cost of management over 20 years is estimated to be: $2911 for catheter ablation, $17467 for surgery and $4959 for medical treatment.

CONCLUSIONS

In the long term transcatheter RF ablation is the most cost-effective treatment strategy for patients with incapacitating supraventricular arrhythmias related to an accessory pathway.

Atrioventricular nodal reentrant tachycardia in patients with ventriculo-atrial conduction block

OBJECTIVE

To demonstrate the reversibility of retrograde ventriculo-atrial block by isoproterenol in patients with atrioventricular nodal reentrant tachycardia (AVNRT).

DESIGN

Three case reports and their electrophysiological features.

PATIENTS

Three patients with documented or suspected paroxysmal supraventricular tachycardia.

INTERVENTIONS

At routine electrophysiology study, no supraventricular tachycardia was inducible in the baseline state. Infusion of isoproterenol (1 to 5 micrograms/min) was given and stimulation procedures were repeated.

RESULTS

At baseline, all three patients had discontinuous antegrade atrioventricular (AV) nodal conduction, but very poor (two patients) or absent (one patient) ventriculo atrial conduction prevented induction of AVNRT. During infusion of isoproterenol, retrograde conduction was enhanced so that 1:1 retrograde occurred to cycle lengths of 300, 340 and 260 ms. AVNRT was then inducible in all patients, reproducing their clinical symptoms.

CONCLUSION

Absent or poor ventriculo-atrial conduction in patients with suspected AV node reentry does not preclude the development of tachycardia with sympathomimetic enhancement. Isoproterenol should be given to attempt reversal of retrograde block in these patients.

Transcatheter radiofrequency ablation. Early experience with supraventricular tachyarrhythmias related to accessory atrioventricular and dual atrioventricular nodal pathways

OBJECTIVE

To describe our initial experience with transcatheter radiofrequency ablation, a useful new treatment for supraventricular tachyarrhythmias related to the presence of an accessory atrioventricular (AV) pathway or dual atrioventricular nodal pathways.

PATIENTS AND METHODS

One hundred and ten patients, including 77 with accessory pathways, 32 with dual atrioventricular (AV) nodal pathways and one with both, underwent electrophysiological studies and were treated with transcatheter radiofrequency ablation in a large metropolitan teaching hospital.

RESULTS

Ninety-five patients (86%) were without evidence of accessory pathway conduction or inducible supraventricular tachycardia and were free of symptoms after a mean follow-up of 13 months (range, 3.0-51 months). Sixty-six of 79 accessory pathways (83.5%) were ablated including 42 of 46 left-sided (91%), 14 of 21 posteroseptal (66%), six of seven anteroseptal (86%), three of four right-sided and one of one midseptal pathways. Thirty-one patients with AV nodal reentry were successfully treated by ablation of either the slow (12 patients) or fast (19 patients) conducting AV nodal pathway. There was a progressive improvement in the success rate of the first procedure from 17% to 64% with the use of large-tip catheters and from 64% to 91% when a purpose-built radiofrequency generator was employed. Complications occurred in nine patients: cardiac tamponade (two patients); mild mitral regurgitation (four); subclavian vein thrombosis (one); transient cerebral ischaemic attack (one); and non-thrombocytic purpuric rash (one). These occurred predominantly during the early experience and were without long-term sequelae. Late in our experience, one patient developed complete atrioventricular block requiring permanent pacemaker implantation.

CONCLUSIONS

In this institution, radiofrequency catheter ablation has been a safe and effective treatment strategy for patients with life-threatening or highly symptomatic supraventricular arrhythmias.

Propafenone-mexiletine combination for the treatment of sustained ventricular tachycardia

OBJECTIVES

The purpose of this study was to explore the efficacy of combined therapy with propafenone and mexiletine for control of sustained ventricular tachycardia.

BACKGROUND

Combination antiarrhythmic drug therapy may enhance efficacy and lead to control of ventricular arrhythmias in some patients. Few reports have studied the combination of class IB and class IC drugs. Thus, this study was designed to investigate a combination of mexiletine and propafenone in patients with refractory ventricular tachycardia.

METHODS

Sixteen patients with sustained ventricular tachycardia had their clinical arrhythmia induced by programmed stimulation. Procainamide and propafenone alone failed to prevent reinduction of tachycardia in all. Mexiletine was subsequently added to propafenone and programmed stimulation was repeated.

RESULTS

With combination therapy ventricular tachycardia was noninducible in three patients (19%). A fourth who had presented with polymorphic ventricular tachycardia had slow bundle branch reentry (cycle length 500 ms) induced. In the other 12, tachycardia cycle length increased from 262 +/- 60 ms at baseline to 350 +/- 82 ms with propafenone and to 390 +/- 80 ms with propafenone plus mexiletine (p less than 0.0001 compared with baseline). Hemodynamic deterioration requiring defibrillation occurred in six patients at baseline study, in five taking propafenone and in two taking both drugs.

CONCLUSIONS

The combination of propafenone and mexiletine is effective in suppressing the induction of ventricular tachycardia in some patients refractory to procainamide and propafenone alone. In those in whom ventricular tachycardia could still be induced, the rate was slower and hemodynamically tolerated.

Efficacy of flecainide for the reversion of acute onset atrial fibrillation

The efficacy and safety of intravenous flecainide to convert recent-onset atrial fibrillation (AF) (present for greater than or equal to 30 minutes and less than or equal to 72 hours and a ventricular response greater than or equal to 120 beats/min) was investigated. A total of 102 patients without severe heart or circulatory failure were randomized to receive either intravenous flecainide (2 mg/kg, maximum dose 150 mg; 51 patients) or placebo (51 patients) in a double-blind trial. Digoxin (500 micrograms intravenously) was administered to all patients who had not previously been receiving digoxin. The electrocardiogram was monitored continuously during the study. In 29 (57%) patients stable sinus rhythm was restored within 1 hour after flecainide and in only 7 (14%) given placebo (chi square 18.9; p = 0.000013; odds ratio 8.3; 95% confidence interval 2.9-24.8). Reversion to sinus rhythm within 1 hour after starting the trial medication was considered a pretrial end point and likely to be due to a drug effect. At the end of the 6-hour monitoring period, 34 patients (67%) in the flecainide group were in sinus rhythm whereas only 18 (35%) in the placebo group had reverted (chi square 8.83, p = 0.003; odds ratio 3.67; 95% confidence interval 1.5-9.1). Significant hypotension, although short lived, was more common in the flecainide group. One patient given flecainide developed torsades de pointes and was successfully electrically cardioverted. Flecainide is useful for the management of recent-onset AF both for control of the ventricular response and conversion to sinus rhythm.(ABSTRACT TRUNCATED AT 250 WORDS)

Long term efficacy of propafenone for prevention of atrial fibrillation

OBJECTIVE

Propafenone, a class IC antiarrhythmic drug, has been successful in the treatment of ventricular and supraventricular arrhythmias. This study retrospectively evaluated the efficacy of propafenone in the prevention of recurrent atrial fibrillation.

DESIGN

Propafenone was given to 81 patients (49 males and 32 females, mean age 61 +/- 16 years) with recurrent atrial fibrillation. The mean dose of propafenone was 701 +/- 235 mg. Patients were monitored for recurrent arrhythmias.

MAIN RESULTS

Long term follow-up over 30 +/- 1.7 months showed 31 patients (38%) remained on propafenone with complete or partial control of atrial fibrillation. The drug was stopped in 35 due to inefficacy, in 12 due to adverse effects, and in three due to desire for ablation therapy.

CONCLUSION

Propafenone may be effective in some patients for long term prevention of atrial fibrillation, although efficacy may decrease over time.

Epicardial mapping in patients with "nodoventricular" accessory pathways

Some patients with electrophysiologic features suggesting nodoventricular fibers have been shown to have right parietal atrioventricular (AV) accessory pathways with decremental conduction properties intraoperatively. The experience with 11 patients (7 women and 4 men, mean age +/- standard deviation 25 +/- 5 years) who had electrophysiologic features consistent with a nodoventricular pathway and who underwent operative correction was reviewed. At electrophysiologic study, all patients had absent or minimal preexcitation in sinus rhythm. During atrial pacing and extrastimulus testing, maximal preexcitation with left bundle branch block morphology developed and the AH and AV intervals progressively prolonged. Preexcited tachycardia was initiated in all patients (AV reentrant tachycardia in 10 patients and AV node reentrant tachycardia in 1 patient). At operation all patients had a right parietal accessory pathway demonstrated. Intraoperative mapping demonstrated the earliest site of ventricular activation during anterograde preexcitation to be at the midanterior right ventricle, consistent with insertion of these pathways into the right bundle branch system, in 7 patients. The ventricular insertion was at the AV groove in 4 patients, in keeping with the typical Wolff-Parkinson-White syndrome. Retrograde conduction over the pathway was not demonstrated in any patient. Two patients had evidence of a second accessory AV pathway in the left paraseptal region. Operative AV node ablation was electively performed in 2 patients without affecting preexcitation in either case. In 1 of these patients, accessory pathway conduction was temporarily abolished by ice mapping in the right anterolateral AV groove.(ABSTRACT TRUNCATED AT 250 WORDS)

Characteristics of accessory pathways exhibiting decremental conduction

The prevalence, electrophysiologic characteristics and functional significance of decremental conduction over an accessory pathway were examined in this retrospective study of 653 patients who had an accessory pathway demonstrated at electrophysiologic study. Decremental conduction was identified in 50 patients (7.6%). In 15 patients with anterograde decremental conduction, the accessory pathway was right parietal or septal in 14 patients and left parietal in 1 patient. In the 40 patients with retrograde decrement, the accessory pathway was left parietal in 19, posteroseptal in 13, right parietal in 2 and right anteroseptal in 6 patients. Anterograde conduction over the accessory pathway was absent in 11 of the 40 patients with retrograde decrement. Retrograde conduction over the accessory pathway was absent in 9 patients with anterograde decrement. There was no significant difference in the accessory pathway effective refractory period, or shortest cycle length with 1:1 conduction over the accessory pathway in anterograde and retrograde directions. The shortest RR interval in atrial fibrillation between 2 preexcited QRS complexes was longer in patients with anterograde decremental conduction than in a control group of patients with anterograde-conducting accessory pathways without decremental properties. These data demonstrate that decremental conduction over accessory pathways is uncommon. Anterograde decremental conduction usually occurs in right-sided or septal pathways that often do not conduct in the retrograde direction.

Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide

Spontaneous reversion to sinus rhythm is a frequent occurrence in recent-onset atrial fibrillation (AF). In a randomized, double-blind, controlled study, intravenous flecainide (2 mg/kg, maximum dose 150 mg) was compared with placebo in the treatment of recent-onset AF (present for greater than or equal to 30 minutes and less than or equal to 72 hours' duration and a ventricular response greater than or equal to 120 beats/min). Intravenous digoxin (500 micrograms) was administered concurrently to all patients in both groups who had not previously taken digoxin. The trial medication was administered over 30 minutes. Exclusion criteria included hemodynamic instability, severe heart failure, recent antiarrhythmic therapy, hypokalemia and pacemaker dependence. One hundred two consecutive patients with recent-onset AF were enrolled in the study. All patients underwent continuous electrocardiographic monitoring in the intensive care or coronary care unit. Twenty-nine (57%) patients given flecainide and digoxin, but only 7 (14%) given placebo and digoxin, reverted to sinus rhythm in less than or equal to 1 hour after starting the trial medication infusion and remained in stable sinus rhythm (chi-square 18.9, p = 0.000013; odds ratio 8.3, 95% confidence interval 2.9 to 24.8). At the end of the 6-hour monitoring period, 34 patients (67%) in the flecainide-digoxin group were in stable sinus rhythm, whereas only 18 patients (35%) in the placebo-digoxin group had reverted (chi-square 8.83, p = 0.003; odds ratio 3.67, 95% confidence interval 1.5 to 9.1).(ABSTRACT TRUNCATED AT 250 WORDS)

Feasibility of long-term electrocardiographic monitoring with an implanted device for syncope diagnosis

Patients with infrequent recurrent syncope undiagnosed after extensive noninvasive and invasive testing pose a diagnostic and therapeutic dilemma. The purpose of this pilot study was to assess the feasibility of using an implanted, long-term monitor as an aid to diagnosis in these patients. This was done using commercially available pacemakers with monitoring functions. Sixteen patients (eight males and eight females), aged 59.7 +/- 17 years who had unexplained syncope despite a 12-lead electrocardiogram, repeated Holter monitoring, exercise testing, echocardiography, an electrophysiological study, and a tilt test (n = 6), were entered into the study. Patients had experienced a mean of 3.1 +/- 1 episodes of syncope in the 12 months prior to the study. All provided a history suggestive of Stokes-Adams attacks and were referred for consideration of pacemaker implantation. Two patients had ischemic heart disease and one patient had a long QT interval. Patients had an Intermedics Nova II or Medtronic Quintech DPG pulse generator capable of recording sensed and paced events implanted with a single right ventricular lead. Syncope or presyncope occurred in ten patients (62%) 4.9 +/- 4.2 months after pacemaker implantation. Bradycardia was detected in six patients and four patients had no arrhythmia. In addition to bradycardia, one patient also had tachycardia detected. Pacing therapy resulted in symptom relief in all six patients with syncope or presyncope due to bradycardia. Complications of pacemaker implantation (lead insulation failure) occurred in two patients. One of these patients subsequently had an infection of the generator pocket with associated systemic sepsis.(ABSTRACT TRUNCATED AT 250 WORDS)

Correlation between the ventricular electrogram amplitude in sinus rhythm and in ventricular fibrillation

During testing of implantable defibrillators, ability to sense ventricular fibrillation is assessed by observing electrograms and the emitted ECG interpretation channel during induced ventricular fibrillation. We hypothesized that ventricular electrogram amplitude in sinus rhythm could be used to predict the ventricular electrogram amplitude in ventricular fibrillation and serve as a first approximation of the "safety margin" for sensing ventricular fibrillation. We compared the peak-to-peak epicardial ventricular electrogram during sinus rhythm and ventricular fibrillation in 12 patients undergoing defibrillator implantation. The ventricular electrogram was recorded with an integrated bipolar lead and filtered at 10-50 Hz. Ventricular fibrillation was induced by alternating current and the ventricular electrogram measured from cessation of alternating current to the first countershock. The mean ventricular electrogram amplitude in sinus rhythm was 15.3 +/- 5.4 mV (range 7.1-25.5) and in 37 episodes of ventricular fibrillation was 8.3 +/- 3.6 mV (range 2.1-16.3). There was a significant relationship between the mean ventricular electrogram amplitude in sinus rhythm and in ventricular fibrillation (R = 0.7, P less than 0.001). There was wide variation among individuals in the decrease in the mean ventricular electrogram amplitude during ventricular fibrillation, with the ratio of mean ventricular electrogram in sinus rhythm to mean ventricular electrogram in ventricular fibrillation ranging from 0.29 to 1.05 (mean 0.55 +/- 0.20). This suggests that up to a fourfold decrease may be expected in the mean ventricular electrogram amplitude during ventricular fibrillation.(ABSTRACT TRUNCATED AT 250 WORDS)

Comparison of meglumine sodium diatrizoate, iopamidol, and iohexol for coronary angiography and ventriculography

Meglumine sodium diatrizoate (Urografin), iopamidol, and iohexol were compared in a double-blind, randomized study of 287 patients undergoing elective cardiac angiography. Ninety-six patients received Urografin, 98 received iopamidol, and 92 received iohexol. The groups were similar in all respects. Variables measured before and after contrast injection were left ventricular end-diastolic pressure (LVEDP), left ventricular systolic pressure (LVSP), systolic arterial pressure (SAP), RR, PR, and QTc intervals, QRS duration, ST segment change greater than 2 mm, arrhythmias, and symptoms. The adequacy of coronary and ventricular opacification was assessed by two experienced observers. Following left ventriculography, small rises in LVEDP occurred with iopamidol and iohexol (mean +/- SD: 18 +/- 7 to 21 +/- 7 mmHg) and a moderate fall in LVSP with Urografin (150 +/- 32 to 133 +/- 32 mmHg). Following coronary angiography there was a progressive fall in SAP (130 +/- 26 to 117 +/- 30 mmHg) and prolongation of RR intervals (900 +/- 138 to 1,266 +/- 692 msec) and QTc (440 +/- 61 to 471 +/- 73 msec) and QRS duration (87 +/- 25 to 100 +/- 27 msec) with Urografin. There was a small fall in SAP with iopamidol (138 +/- 25 to 128 +/- 27 mmHg) and prolongation of QRS duration with iohexol (85 +/- 29 to 90 +/- 24 msec). Other parameters were not significantly affected. Frequent bradyarrhythmias (sinus pause 14.5%, asystole 6%) and ST segment depression occurred following Urografin. Urografin was less well tolerated, with 10% of patients experiencing severe nausea or vomiting and 30% of patients experiencing extreme heat sensation. Differences between iohexol and iopamidol were minor.(ABSTRACT TRUNCATED AT 250 WORDS)

Management of the patient with the Wolff-Parkinson-White syndrome

Patients with ventricular preexcitation may have symptomatic arrhythmias (Wolff-Parkinson-White syndrome) which can range from life-threatening, to disabling symptoms or minimal symptoms. Individuals may also be entirely asymptomatic. A rational approach to the management of these individuals is therefore dependent on the clinical circumstances. This review discusses the value and limitations of some of the available noninvasive and invasive investigations which may contribute to the successful management of these patients. In general, investigations are useful for establishing the diagnosis, identifying those patients at risk from life-threatening arrhythmias and providing a rational basis for therapy. The available pharmacologic and nonpharmacologic therapeutic options are discussed.

Effect of alpha 1-adrenoceptor blockade on ventricular ectopic beats inacute myocardial infarction

Experimental studies have shown that alpha1-adrenoceptor blockade can reduce ventricular arrhythmia associated with myocardial ischaemia. To examine the efficacy of prazosin in clinical acute infarction 38 patients were randomized, on presentation, to prazosin or placebo. Oral therapy was commenced at 0.5 mg, incremented and continued for seven days, Holter recordings being obtained for the first 48 hours and on day 7. The final dose of prazosin was 2.5 +/- 1.7 (SD) mg and placebo, 3.1 +/- 2.0 mg. During dose titration in the first 24 hours, and on day 7, there was no difference in ventricular ectopic beats. In the second 24 hours, ventricular ectopic beats averaged two per hour in the prazosin group (n = 9) and 60 per hour in placebo (n = 15) (P = 0.05, Mann-Whitney rank testing). The results indicate that alpha1-adrenoceptor blockade may reduce ventricular arrhythmia in clinical acute myocardial infarction. While early and adequate therapy is currently limited by vasodilation, this small study suggests that more extensive clinical trials will be warranted as relatively cardio-selective alpha1-adrenoceptor blocking drugs are developed.

Long term efficacy of transvenous catheter ablation of the atrioventricular junction for refractory supraventricular tachycardia

Twenty-four patients who underwent transvenous catheter ablation of the atrioventricular (A-V) junction between November 1982 and February 1987 were followed from 18-72 months (mean 47.9) to assess the long term efficacy and safety of the procedure. All had severely symptomatic supraventricular tachyarrhythmias refractory to standard treatment. Atrioventricular conduction was abolished in 23 patients, 22 having permanent pacemakers implanted. Conduction has recovered, though it is modified, in one patient who is asymptomatic on digoxin. Four patients have died; one suddenly 20 months following the procedure, one of progressive heart and liver failure due to hemochromatosis, and two of a stroke. Four patients have had complications related to permanent pacing; one patient has required generator replacement and one patient ventricular lead replacement, one patient had asystole and one patient had a pacemaker-related tachycardia. Two patients remain symptomatic but improved by the procedure. Seventeen patients are free of their original symptoms, 11 having no intervening morbid events. These results demonstrate that patients with severely symptomatic supraventricular tachyarrhythmias may gain long term symptomatic relief from the procedure, but permanent pacing is a cause of significant morbidity and there is a small incidence of late sudden cardiac death.

Day case cardiac catheterisation--a safe and economic alternative

Cardiac catheterisation, as a day procedure, has been performed at the Royal Perth Hospital since November 1985. During the 23 month period from November 1985 to September 1987, there have been 1398 day procedures carried out. One hundred and twelve patients (8%) required overnight admission as a consequence of the procedure--39 patients for routine observation, 41 patients for minor hemorrhage from the brachial arteriotomy or femoral artery puncture site; 12 patients for severe angina: three patients with reversible ischemic neurological deficits; two patients with stroke; four patients with transient brachial artery occlusion; two patients with arrhythmias and eight patients for miscellaneous reasons. One patient discharged on the day of the procedure required subsequent re-admission for treatment of an acute myocardial infarction. There were no deaths. The financial cost saving to the hospital in real terms is estimated to be $41.50 per patient and to the community a further saving of $25 per patient due to a reduction in sick leave. The minimum total cost saving to the taxpayer for the 1,285 patients managed as day cases was $85,000. Cardiac catheterisation can be performed as a day procedure with low morbidity, low mortality and modest cost savings to a major hospital.

Haemolytic disease of the newborn in Western Australia 1974 to 1976

The prophylactic use of anti-Rh (D) immunoglobulin has resulted in a marked decline in the incidence of Rh haemolytic disease of the newborn (HDN) since its introduction in 1968. Nevertheless, cases still occur. Those recorded in the metropolitan area of Western Australia in the 3 years, 1974 to 1976, have been studied in detail. There were 29 cases of ABO haemolytic disease, among which there were no deaths, and 56 cases of Rh haemolytic disease with 9 perinatal deaths. Nearly half of the mothers of the infants with Rh HDN were first immunised before anti-D became available; a quarter had not been given anti-D when it was required, and a few had formed Rh antibodies in their first pregnancy or despite treatment with anti-D.